Relationship among plasma secretory phospholipase A2, oxidized low density lipoprotein & paraoxonase activities in hypertensive subjects treated with angiotensin converting enzyme inhibitors

Indian Journal of Medical Research

Volumn 129, Issue 4, 2009, Pages 390-394

  Konukoglu, Dildar ^a,c   Firtina, Sinem ^a   Serin, Ozden ^b   Cavusoglu, Coskun ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c NONE   (Turkey)

Author keywords

Hypertension; Inflammation markers; Oxidized low density lipoprotein; Paraoxonase; Secretory phospholipase A2

Indexed keywords

ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; ANTIHYPERTENSIVE AGENT; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2 GROUP II;

ADULT; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE MARKER; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HYPERTENSION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; THERAPY EFFECT; ANALYSIS OF VARIANCE; BLOOD; BODY MASS; ENZYME LINKED IMMUNOSORBENT ASSAY; MIDDLE AGED; TURKEY (REPUBLIC);

ADULT; ANALYSIS OF VARIANCE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ARYLDIALKYLPHOSPHATASE; BODY MASS INDEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUP II PHOSPHOLIPASES A2; HUMANS; HYPERTENSION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; TURKEY;

EID: 70149108412     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kakar P, Lip GY. Hypertension: endothelial dysfunction, the prothrombotic state and antithrombotic therapy. Expert Rev Cardiovasc Ther 2007; 5: 441-5.
2. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005; 1: 183-98.
3. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 2001; 280: C719-41.
4. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003; 108: 2041-8.
5. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J 2001; 15: 2073-84.
6. Kougias P, Chai H, Lin PH, Lumsden AB, Yao Q, Chen C. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 2006; 12: RA5-16.
7. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996; 7: 69-76.
8. Rozenberg O, Rosenblat M, Coleman R, Shib DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003; 34: 774-84.
9. Spirou A, Rizos E, Liberopoulos EN, Kolaitis N, Achimastos A, Tselepis AD, et al. Effect of barnidipine on blood pressure and serum metabolic parameters in patients with essential hypertension: a pilot study. J Cardiovasc Pharmacol Ther 2006; 11: 256-61.
10. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressure-independent effect of valsartan. Diabetes Res Clin Pract 2006; 74: 201-3.
11. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-90.
12. [No authors listed]. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151-85.
13. World Health Organization. WHO document. Measuring obesity-classification and description of anthropometric data. Report of a WHO Regional office consultation on the epidemiology of obesity. Copenhagen, Denmark: WHO Regional Office for Europe, Nutrition Unit Document EUR/ICP/NUT 1998; 125-42.
14. Hasselwander O, Savage DA, Mc Master D, Houghrey CM, McNammee PT, Middleton D, et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int 1999; 56: 289-98.
15. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
16. Saadeddin SM, Habbab MA, Ferns GA. Markers of inflammation and coronary artery disease. Med Sci Monit 2002; 8: RA5-12.
17. Frostegard J, Wu R, Lemne C, Thulin T, Witztum JL, de Faire U. Circulating oxidized low-density lipoprotein is increased in hypertension. Clin Sci (Lond) 2003; 105: 615-20.
18. Tietge UJ, Pratico D, Ding T, Funk CD, Hildebrand RB, Van Berkel T, et al. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res 2005; 46: 1604-14.
19. Xu XP, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999; 99: 993-8.
20. Leitinger N, Watson AD, Hama SY, Ivandic B, Qiao JH, Huber J, et al. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 1999; 19: 1291-8.
21. Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003; 23: 461-7.
22. Watanabe T, Pakala R, Katagiri T, Benedict CR. Mildly oxidized low-density lipoprotein acts synergistically with angiotensin II in inducing vascular smooth muscle cell proliferation. J Hypertens 2001; 19: 1065-73.
23. Chen J, Mehta JL. Interaction of oxidized low-density lipoprotein and the renin-angiotensin system in coronary artery disease. Curr Hypertens Rep 2006; 8: 139-43.
24. Djordjevic VB, Pavlovic D, Pejovic M, Cvetkovic T, Lecic N, Deljanin-Ilic M. Changes of lipid peroxides and antioxidative factors levels in blood of patients treated with ACE inhibitors. Clin Nephrol 1997; 47: 243-7.
25. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 2004; 110: 1903-8.
26. Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003; 41: 1096-101.
27. Uzun H, Karter Y, Aydin S, Curgunlu A, Simsek G, Yucel R, et al. Oxidative stress in white coat hypertension; role of paraoxonase. J Hum Hypertens 2004; 18: 523-8.
28. Saruhan E, Olgun A, Ozturk K, Akman S, Erbil MK. Age-related paraoxonase activity changes in Turkish population. Ann NY Acad Sci 2007; 1100: 218-22.
29. Agachan B, Isbir CS, Ergen HA, Yilmaz H, Yaylim I, Zeybek U, et al. No association between paraoxonase 192 and 55 polymorphism and increasing risk of coronary artery disease in Turkish patients. Adv Mol Med 2005; 2: 92-6.